ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Research Article

Trends in prevalence and patterns of use of a heated tobacco product (IQOSTM) in Japan: A three-year repeated cross-sectional study

[version 1; peer review: 2 approved with reservations]
PUBLISHED 30 Jun 2022
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the Global Public Health gateway.

Abstract

Background: Numerous smoke-free tobacco or nicotine-containing product (TNP) alternatives have been introduced to support individual- and population-level harm reduction relative to continued cigarette smoking. This article details the nationwide prevalence and patterns of TNP use between 2016 and 2019 in Japan following the commercialization of IQOSTM, a smoke-free heated tobacco product (HTP).
Methods: Cross-sectional surveys were conducted over a period of three study years (2016/2017, 2017/2018, and 2018/2019) in representative samples of the Japanese general adult population and samples of Japanese adult IQOS users registered in the IQOS owner database of Philip Morris International’s affiliate in Japan.
Results: Across the three study years (Y1-Y3), the prevalence of overall current TNP use (Y1-Y3: 18.5%, 18.9%, and 18.2%) and overall TNP use by age and sex remained similar. However, there was a growing shift from cigarette smoking to smoke-free TNP use across the three study years. While the cigarette smoking prevalence (Y1-Y3: 17.6%, 17.3%, and 16.0%) decreased, the use prevalence of smoke-free TNPs, including the HTP IQOS (Y1-Y3: 1.8%, 3.2%, and 3.3%) and e-cigarettes (Y1-Y3, 0.7%, 1.6%, and 2.0%) increased. At the same time, TNP initiation, TNP relapse, and TNP reinitiation with IQOS were all very low across the three study years. Across Y1-Y3, exclusive use of only one type of TNP (Y1-Y3: 82.3%, 75.0%, and 70.4%) decreased, while dual use of two types of TNPs (Y1-Y3: 14.3%, 17.2%, and 16.7%) increased, and poly-TNP use (Y1-Y3: 2.1%, 6.1%, and 10.0%) increased markedly. Moreover, the majority of adult IQOS users were exclusive IQOS users.
Conclusions: These findings suggest that current IQOS use behavior trends are in line with the principles of tobacco harm reduction and that HTPs are effective tools for complementing current tobacco control measures.

Keywords

Tobacco harm reduction, heated tobacco, smoke-free, IQOS, use patterns, prevalence, smoking initiation, smoking reinitiation

Introduction

It is well established that cigarette smoking can lead to numerous negative health outcomes, including premature and preventable death1. The burden of smoking on individual and population health has driven health authorities and regulatory bodies to recommend and implement various tobacco control policies2. Never initiating or quitting smoking are the most direct ways to alleviate the health burden of smoking3. However, strategies aimed at preventing smoking and promoting cessation continue to face numerous challenges, including smokers who are not motivated to quit or who relapse/reinitiate smoking after a period of abstinence2,4,5. While smoking prevalence has declined over the last decades, over 1 billion people globally continue to smoke combustible tobacco products today1,6, and cigarette smoking continues to be responsible for the largest number of preventable deaths worldwide7,8.

To complement tobacco control efforts9, tobacco harm reduction strategies have been introduced around the world10,11. Tobacco harm reduction includes prevention of tobacco or nicotine-containing product (TNP) use initiation and reinitiation2,11,12 while ensuring that adult smokers switch completely from combustible TNPs to less harmful smoke-free (i.e., non-combustible) TNPs13,14.

Unlike cigarettes, which burn tobacco and produce a complex mixture of harmful and potentially harmful constituents (HPHC) through combustion, IQOSTM, a smoke-free heated tobacco product (HTP) developed by Philip Morris International (PMI), heats a specifically engineered tobacco stick (i.e., HEETSTM/HeatSticksTM) to temperatures below the level of combustion15. As a consequence, smokers who switch completely to IQOS use are exposed to much lower levels of HPHCs than those who continue smoking cigarettes1620.

As part of PMI’s commitment to a smoke-free future, IQOSTM was introduced in Japan in 2014 and is now available in more than 70 countries worldwide, with an estimated 21 million adult users globally21. The availability and demand for IQOS as an alternative to cigarettes has raised the need to monitor IQOS use prevalence and use patterns with the aim of informing public health authorities locally and worldwide. Such findings will further enable regulators to delineate the role of IQOS in harm reduction as a viable substitute for cigarettes2,22.

Building on the reporting of Afolalu et al.23, the aim of the current study was to analyze the temporal trends in TNP use in nationally representative samples of the Japanese general adult population (JGAP) and, separately, in samples of Japanese adult IQOS users (JAIQOS) from PMI’s adult IQOS owner database in Japan across three recent years (2016/2017, 2017/2018, and 2018/2019).

Participants and methods

Setting

Cross-sectional surveys in representative samples of the Japanese general adult population (JGAP) and, separately, in samples of Japanese adult IQOSTM users (JAIQOS) registered in the IQOS owner database of Philip Morris International (PMI)’s affiliate in Japan were initiated in December 2016 and repeated annually over three full calendar years from 2016/2017 to 2018/2019 (Figure 1). Considering that IQOS was relatively new on the Japanese TNP market in 2016, the IQOS use prevalence in the JGAP was expected to be low. Therefore, additional surveys among JAIQOS were conducted alongside the JGAP surveys to obtain reliable estimates of IQOS use patterns among Japanese adult IQOS users23.

4e200ad8-84bf-4e50-a671-048098f11645_figure1.gif

Figure 1. Overall survey study design for the JGAP and JAIQOS samples in each wave of the 3-year study period (2016/2017, 2017/2018, and 2018/2019) of the survey fielding.

Abbreviations: ICF, informed consent form; JAIQOS, sample of adult Japanese IQOS users from PMI’s IQOS owner database in Japan; JGAP, representative sample of the Japanese general adult population; PMI, Philip Morris International.

Participants and study design

Study participants

To be included in the JGAP or JAIQOS samples, individuals had to be of legal age for purchasing TNPs in Japan (i.e., ≥20 years), current residents of Japan, and fluent in Japanese. Those included in the JAIQOS samples also had to have used >100 HEETSTM/HeatSticksTM in their lifetime24, be a current user of IQOS with HEETS/HeatSticks, have access to the internet, and not be currently employed by PMI or its affiliates.

JGAP — Sampling, sample size, and survey mode

The JGAP samples were obtained via a syndicated (Omnibus) survey overseen and coordinated by Ipsos UK Ltd (London, UK). The fieldwork provider in Japan was Central Research Services Inc (Tokyo, Japan). The Omnibus surveys employed a three-stage stratified proportional sampling strategy that included the whole country. In stage 1, sampling points in the 12 Japanese administrative regions were allocated on the basis of their share of the population25. Households within each sampling point were identified in Stage 2 by using an electronic residential map, from which about 40 households were randomly selected. In the final stage 3, participants who met the inclusion criteria were selected from within the sampled households. Within each sampling point, quotas on age and sex were set to ensure the representativeness of the Japanese population.

The annual JGAP sampling consisted of four approximately equal-sized waves spaced throughout each study year to account for potential seasonal differences (Figure 2). A sample size of 5,000 participants per year was sufficient to estimate an IQOSTM use prevalence of 5.0% with 95% confidence and a precision of ±0.6% units. In the third year, six survey waves (7,000 participants) were conducted to increase the sample size and improve the accuracy of the estimates.

4e200ad8-84bf-4e50-a671-048098f11645_figure2.gif

Figure 2. Allocation of the JGAP and JAIQOS survey waves over the 3-year study period (2016/2017, 2017/2018, and 2018/2019).

Abbreviations: JAIQOS, sample of adult Japanese IQOS users from PMI’s IQOS owner database in Japan; JGAP, representative sample of the Japanese general adult population; PMI, Philip Morris International; W, survey wave.

The JGAP surveys were conducted at participants’ homes through in-person face-to-face pen-and-paper interviews. However, to avoid any bias on basis of social desirability of their response regarding their personal TNP use, the participants were handed the “Tobacco Use Prevalence” questionnaire section for self-completion. For completing the Omnibus questionnaires, each participant was given a coupon for JPY 500 (approximately USD 4).

JAIQOS — Sampling, sample size, and survey mode

Upon purchasing an IQOSTM device, users were invited to register in the PMI Japan IQOS owner database, which included about 350,000 adult IQOS owners in July 2017 and reached close to six million in 2019. Considering the demographic age-sex distribution of the database, individuals were randomly selected from the database and invited by email to participate in the survey for each wave.

A sample size of 2,000 participants per year was sufficient to estimate a 50% proportion of exclusive IQOS use with 95% confidence and a precision of ±2.19% units. Each annual IQOS user sample consisted of four approximately equal-sized waves spaced throughout each study year to account for potential seasonal differences (Figure 2), with the aim of recruiting 500 adult participants per wave. The JAIQOS surveys were conducted entirely online through computer-assisted self-interviewing. For completing the online survey, participants were given a gift code valued at JPY 500 (about USD 4). The existing standard TNP use questions are available in the literature.

Survey questionnaires

For the present study, the “Tobacco Use Prevalence” questionnaire was developed on the basis of several existing standard TNP use questions available in the literature to capture information about TNP use; the questionnaire was not specifically validated. In both the JGAP and JAIQOS samples, the same questionnaire was used. However, while for the JGAP samples a pen-and-paper self-completion survey mode was used, for the JAIQOS samples an online mode was applied. The survey questions can be found in the Extended data.

Ethical conduct of the study

All subjects gave informed consent for inclusion in the study prior to participation. The participants of the JGAP samples gave verbal consent that was recorded by the interviewers as part of the Omnibus interviews, while the participants of the JAIQOS samples provided written consent. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and were consistent with Good Epidemiological Practice (GEP)26. The study protocol, including the procedures of providing informed consent, were approved by the Hakata Clinic Institutional Review Board (Reference ID: J-186) in Fukuoka, Japan.

Analytical methods

Analyses were conducted using SAS v9.4 (or higher; SAS Inc., Cary, North Carolina, USA). For both the JGAP and JAIQOS samples, data were analyzed and summarized descriptively for each study year. For participant characteristics and outcome measures, continuous data are presented as mean and standard deviation (SD) or 95% confidence intervals (CI) and categorical data as number and percentage (95% CI) for the total samples and/or stratified by age and sex. Missing data were not included in the statistical analyses.

The following definitions were applied: “Use/never use” of cigarettes or IQOSTM with HEETSTM/HeatSticksTM: having/not having used 100 cigarettes or 100 HEETS/HeatSticks in the lifetime, to differentiate established cigarette or IQOS users from triers or experimenters24. “Current use”: daily or nondaily use of a TNP at the time of the survey. “Exclusive”, “dual”, and “poly” use: current use of only one type, two types, or three or more types of TNPs, respectively. “Initiation”: the time point at which a participant started established use/smoking of a TNP. “Initiation rate”: proportion of initiation in the last 12 months among never TNP users. “Relapse” and “reinitiation”: restarting TNP use following a period of quitting all TNPs for ≤12 months and >12 months, respectively.

Prevalence of current TNP use for overall TNPs or by TNP category (cigarettes, IQOS, e-cigarettes, etc.) was calculated in the JGAP samples. For both JGAP and JAIQOS samples, the following was calculated: response rates, sample characteristics, and patterns of TNP use (JGAP: exclusive, dual, and poly use; JAIQOS: exclusive IQOS use and IQOS use with combustible or smoke-free TNP) as well as frequency (past 30-day use), intensity (average daily consumption), and history (JGAP: initiation, relapse, and reinitiation with IQOS; JAIQOS: previous cigarette smoking history before starting IQOS use) of TNP use.

Results

Survey dispositions and outcome rates

Regarding survey dispositions and outcome rates (Figure 3), the JGAP samples had a response rate of >30% in each of the three study years (Y1-Y3), which resulted in sample sizes of 4,878, 4,791, and 7,236 for Y1-Y3 of the Omnibus survey, respectively. In the Y1-Y3 JAIQOS samples, response rates of 19.4%, 4.7%, and 2.0% yielded sample sizes of 2,000, 2,044, and 2,013, respectively.

4e200ad8-84bf-4e50-a671-048098f11645_figure3.gif

Figure 3. Flow diagram of study samples and survey dispositions in the JGAP and JAIQOS samples.

Abbreviations: JAIQOS, sample of adult Japanese IQOS users from PMI’s IQOS owner database in Japan; JGAP, representative sample of the Japanese general adult population; n1-n3, sample sizes for study years 1–3, respectively; PMI, Philip Morris International.

Sample characteristics

JGAP samples

Overall, the demographic characteristics of the JGAP samples were similar across Y1-Y3 (Table 1) and comparable with those of the Japanese adult population25. The mean (±SD) ages of the Y1-Y3 samples were 53.8 (±17.9), 54.5 (±17.6), and 54.8 (±17.8) years, respectively, and each of the samples included slightly more women (Y1-Y3: 51.9%, 53.3% and 53.2%) than men (Y1-Y3: 48.1%, 46.7%, and 46.8%), mirroring the female skew in the actual Japanese population25.

Table 1. Sample characteristics of the JGAP and JAIQOS samples.

Japanese
population
(2016)*
(%)
Number (n) and percentage (% [95% CI])
Year 1 (2016/2017)Year 2 (2017/2018)Year 3 (2018/2019)
JGAP
(N=4,878)
JAIQOS
(N=2,000)
JGAP
(N=4,791)
JAIQOS
(N=2,044)
JGAP
(N=7,236)
JAIQOS
(N=2,013)
Sex
  Men48.32,345
48.1 [46.6–49.5]
1,632
81.6 [79.8–83.3]
2,238
46.7 [45.2–48.2]
1,641
80.3 [78.4–82.0]
3,385
46.8 [45.6–48.0]
1,609
79.9 [78.1–81.7]
  Women51.72,533
51.9 [50.5–53.4]
368
18.4 [16.7–20.2]
2,553
53.3 [51.8–54.8]
403
19.7 [18.0–21.6]
3,851
53.2; [52.0–54.4]
404
20.1 [18.3–21.9]
Age (years)
  20–2912528
10.8 [9.9–11. 8]
420
21.0 [19.2–22.9]
464
9.7 [8.8–10.6]
346
16.9 [15.3–18.7]
704
9.7 [9–10.5]
330
16.4 [14.8–18.1]
  30–3915.1723
14.8 [13.8–15.9]
736
36.8 [34.6–39.0]
668
13.9 [12.9–15.0]
710
34.7 [32.6–36.9]
978
13.5 [12.7–14.4]
710
35.3 [33.1–37.5]
  40–4917.8873
17.9 [16.8–19.1]
568
28.4 [26.4–30.5]
886
18.5 [17.4–19.7]
642
31.4 [29.4–35.5]
1,336
18.5 [17.5–19.4]
644
32.0 [29.9–34.1]
  50+55.22,754
56.5 [55.0–57.9]
276
13.8 [12.3–15.4]
2,773
57.9 [56.4–59.3]
346
16.9 [15.3–18.7]
4,218
58.3 [57.1–59.5]
329
16.3 [14.7–18.1]
  Mean [±SD]-53.8 [±17.9]38.5 [±9.7]54.5 [±17.6]39.7 [±10.1]54.8 [±17.8]39.9 [±9.9]
Education
  Junior high school8.6454
9.3 [8.5–10.2]
124
6.2 [5.1–7.4]
417
8.7 [7.9–9.6]
139
6.8 [5.7–8.0]
619
8.6 [7.9–9.3]
151
7.5 [6.3–8.8]
  High school40.12,395
49.1 [47.6–50.6]
726
36.3 [34.1–38.5]
2,433
50.8 [49.3–52.3]
753
36.8 [34.7–39.0]
3,603
49.8 [48.6–51]
744
37.0 [34.8–39.2]
  College/University41.81,980
40.6 [39.2–42.0]
1,135
56.8 [54.5–59.0]
1,917
40.0 [38.6–41.5]
1,114
54.4 [52.3–56.7]
2,967
41.0 [39.8–42.2]
1,085
53.9 [51.6–56.1]
  Don’t know/NA9.549
1.0 [0.7–1.4]
15
0.8 [0.4–1.3]
24
0.5 [0.3–0.8]
38
1.9 [1.3–2.6]
47
0.6 [0.4–0.9]
33
1.6 [1.1–2.3]
Occupation
  Farming/Agriculture/Fishery-80
1.6 [1.3–2.1]
8
0.4 [0.1–0.8]
89
1.9 [1.4–2.3]
15
0.7 [0.4–1.3]
165
2.3 [1.9–2.7]
18
0.9 [0.5–1.5]
  Self-employed/Small private business12.1538
11.0 [10.1–12.0]
329
16.5 [14.8–18.2]
511
10.7 [9.8–11.6]
347
17.0 [15.3–18.7]
848
11.7 [10.9–12.5]
354
17.6 [15.9–19.4]
  Clerical employee-927
19.0 [17.9–20.2]
284
14.2 [12.6–15.9]
845
17.6 [16.5–18.8]
228
11.2 [9.8–12.6]
1,289
17.8 [16.9–18.8]
271
13.5 [12–19.4]
  Manual employee-1,063
21.8 [20.6–23.0]
268
13.4 [11.9–15.0]
1,094
22.8 [21.6–24.1]
272
13.3 [11.8–14.9]
1,560
21.6 [20.6–22.6]
253
12.6 [11.1–14.1]
  Managing profession46.9118
2.4 [2.0–2.9]
414
20.7 [18.9–22.6]
108
2.3 [1.8–2.8]
432
21.1 [19.3–23.0]
197
2.7 [2.3–3.2]
398
19.8 [18.0–21.6]
  Housewife19.91,211
24.8 [23.6–26.1]
84
4.2 [3.3–5.2]
1,175
24.5 [23.3–25.8]
115
5.6 [4.6–6.8]
1,791
24.8 [23.7–25.8]
95
4.7 [3.8–5.8]
  Student2106
2.2 [1.7–2.7]
37
1.9 [1.3–2.6]
82
1.7 [1.3–2.2]
34
1.7 [1.1–2.4]
160
2.2 [1.8–2.6]
28
1.4 [0.9–2.1]
  Retired/Unemployed19.1835
17.1 [16.0–18.3]
26
1.3 [0.8–1.9]
887
18.5 [17.3–19.7]
69
3.4 [2.6–4.3]
1,226
16.9 [16–17.9]
43
2.1 [1.5–2.9]
  Don’t know/NA-NA550
27.5 [25.5–29.6]
NA532
26.0 [24.1–28.0]
NA553
27.5 [25.5–29.5]
Region
  Chubu-964
19.8 [18.6–21.0]
310
15.5 [13.9–17.2]
908
19.0 [17.8–20.1]
288
14.1 [12.6–15.7]
964
19.8 [18.6–21.0]
285
14.2 [12.6–15.8]
  Chugoku-294
6.0 [5.3–6.8]
94
4.7 [3.8–5.8]
281
5.9 [5.2–6.6]
95
4.6 [3.7–5.7]
294
6.0 [5.3–6.8]
87
4.3 [3.4–5.4]
  Hokkaido-219
4.5 [3.9–5.2]
58
2.9 [2.2–3.8]
214
4.5 [3.8–5.1]
93
4.5 [3.6–5.6]
219
4.5 [3.9–5.2]
93
4.6 [3.7–5.7]
  Kanto-1,585
32.5 [31.1–33.9]
871
43.6 [41.3–45.8]
1,610
33.6 [32.2–35.0]
827
40.5 [38.3–42.7]
1,585
32.5 [31.1–33.9]
833
41.4 [39.2–43.6]
  Kinki-757
15.5 [14.5–16.6]
342
17.1 [15.4–18.9]
728
15.2 [14.1–16.3]
349
17.7 [15.4–18.8]
757
15.5 [14.5–16.6]
333
16.5 [14.9–18.3]
  Kyusyu-549
11.3 [10.3–12.2]
148
7.4 [6.2–8.7]
553
11.5 [10.6–12.5]
190
9.3 [8.0–10.7]
549
11.3 [10.3–12.2]
177
8.8 [7.5–10.2]
  Shikoku-161
3.3 [2.8–3.9]
41
2.1 [1.4–2.8]
142
3.0 [2.5–3.5]
38
1.9 [1.3–2.6]
161
3.3 [2.8–3.9]
37
1.8 [1.2–2.6]
  Tohoku-349
7.2 [6.4–8.0]
136
6.8 [5.7–8.0]
355
7.4 [6.6–8.2]
164
8.0 [6.8–9.3]
349
7.2 [6.4–8.0]
168
8.3 [7.1–9.7]

Abbreviations: CI, confidence interval; JAIQOS, sample of adult Japanese IQOS™ users from PMI’s IQOS owner database in Japan; JGAP, representative sample of the Japanese general adult population; NA, not applicable; PMI, Philip Morris International; SD, standard deviation.

*Source: Statistics Bureau of Japan (2015) Source on Education: Statistics Bureau of Japan (2010) Source on Occupation: Public Opinion Survey on the Life of the People (23 June - 10 July 2016).

In each of Y1-Y3, a larger proportion of the sample was based in a major city (Y1-Y3: 27.4%, 28.1%, and 28.6%) than in rural areas (Y1-Y3: 10.0%, 9.3%, and 8.8%). Across Y1-Y3 (Table 1), most of the samples reported high school (Y1-Y3: 49.1%, 50.8%, and 49.8%) or college/university (Y1-Y3: 40.6%, 40.0%, and 41.0%) as the highest level of education, and the most common occupations were homemaker (Y1-Y3: 24.8%, 24.5%, and 24.8%), manual employee (Y1-Y3: 21.8%, 22.8%, and 21.6%), and clerical employee (Y1-Y3: 19.0%, 17.6%, and 17.8%).

JAIQOS samples

Overall, the demographic characteristics of the JAIQOS samples were similar across Y1-Y3 (Table 1). The mean (±SD) ages of the Y1-Y3 samples were 38.5 (±9.7), 39.7 (±10.1), and 39.9 (±9.9) years, respectively, and in each of the samples there were more men (Y1-Y3: 81.6%, 80.3%, and 79.9%) than women (Y1-Y3: 18.4%, 19.7%, and 20.1%).

Across Y1-Y3 (Table 1), most of the participants reported completing college/university (Y1-Y3: 56.8%, 54.4%, and 53.9%) or high school (Y1-Y3: 36.3%, 36.8%, and 37.0%), and the most common occupations were manager (Y1-Y3: 20.7%, 21.1%, and 19.8%) and self-employed/small business owner (Y1-Y3: 16.5%, 17.0%, and 17.6%).

TNP use in JGAP samples

Prevalence of overall TNP use

Across Y1-Y3, the prevalence of overall current (Y1-Y3: 18.5%, 18.9%, 18.2%) former (Y1-Y3: 18.7%, 16.3%, 16.9%), and never (Y1-Y3: 62.9%, 64.8%, 64.9%) TNP use as well as of TNP use by age and sex were similar (Table 2).

Table 2. Prevalence of overall current, former, and never TNP use in the JGAP samples overall and by sex and age group.

Number (n) and percentage (% [95% CI])
Current TNP usersFormer TNP usersNever TNP users
Age
Group
(years)
Year 1
(2016/2017)
Year 2
(2017/2018)
Year 3
(2018/2019)
Year 1
(2016/2017)
Year 2
(2017/2018)
Year 3
(2018/2019)
Year 1
(2016/2017)
Year 2
2017/2018)
Year 3
(2018/2019)
AllAll894
18.5 [17.3–19.6]
900
18.9 [17.7–20.1]
1,304
18.2 [17.2–19.1]
905
18.7 [17.5–19.9]
777
16.3 [15.2–17.4]
1,211
16.9 [16.0–17.8]
3,044
62.9 [61.4–64.3]
3,086
64.8 [63.4–66.2]
4,656
64.9 [63.8–66.1]
20–29110
20.8 [17.4–24.6]
84
18.1 [14.7–22]
129
18.4 [17.2–19.1]
30
5.7 [3.8–8.1]
25
5.4 [3.5–7.9]
40
5.7 [4.1–7.8]
388
73.5 [69.5–77.3]
354
76.5 [72.3–80.3]
531
75.9 [72.5–79]
30–39180
25.0 [21.8–28.4]
173
26.0 [22.6–29.5]
244
25.2 [15.6–21.6]
115
16.0 [13.3–18.9]
92
13.8 [11.2–16.7]
143
14.8 [12.5–17.2]
425
59.0 [55.3–62.7]
401
60.2 [56.3–64]
581
60.0 [56.8–63.2]
40–49222
25.5 [22.6–28.6]
213
24.2 [21.3–27.2]
314
23.7 [22.4–28.1]
145
16.7 [14.2–19.4]
136
15.4 [13.1–18]
200
15.1 [13.2–17.2]
502
57.8 [54.4–61.1]
532
60.4 [57–63.7]
809
61.1 [58.4–63.8]
50+382
14.0 [12.7–15.4]
430
15.6 [14.2–17.1]
617
14.8 [13.6–15.9]
615
22.6 [21–24.2]
524
19.0 [17.5–20.6]
828
19.8 [18.6–21.1]
1729
63.4 [61.5–65.3]
1,799
65.3 [63.5–67.2]
2,735
65.4 [63.9–66.9]
MenAll683
29.4 [27.5–31.4]
686
30.9 [29–33]
994
29.7 [28.1–31.3]
723
31.1 [29.2–33.1]
620
28.0 [26.1–29.9]
965
28.8 [27.2–30.4]
916
39.4 [37.4–41.5]
911
41.1 [39–43.2]
1,389
41.5 [39.8–43.2]
20–2974
27.6 [22.3–33.4]
62
27.7 [21.9–34.1]
86
24.0 [19.6–28.8]
19
7.1 [4.3–10.9]
12
5.4 [2.7–9.2]
24
6.7 [4.3–9.9]
175
65.3 [59.2–71]
150
67.0 [60.3–73.1]
248
69.3 [64.2–74.1]
30–39142
36.0 [31.2–41]
139
40.3 [35–45.7]
189
37.3 [33–41.7]
68
17.3 [13.6–21.4]
55
15.9 [12.2–20.3]
90
17.8 [14.5–21.4]
184
46.7 [41.6–51.8]
151
43.8 [38.4–49.2]
228
45.0 [40.5–49.5]
40–49162
38.9 [34.2–43.9]
155
37.0 [32.3–41.9]
241
37.4 [33.6–41.3]
102
24.5 [20.4–29]
96
22.9 [18.9–27.3]
143
22.2 [19–25.7]
152
36.5 [31.9–41.4]
168
40.1 [35.3–45]
260
40.4 [36.5–44.3]
50+305
24.5 [22.1–27.1]
330
26.9 [24.3–29.5]
478
26.0 24.0–28.1]
534
42.9 [40.1–45.8]
457
37.2 [34.4–40]
708
38.5 [36.2–40.8]
405
32.6 [29.9–35.3]
442
36.0 [33.2–38.8]
653
35.5 [33.3–37.8]
WomenAll211
8.4 [7.3–9.6]
214
8.4 [7.3–9.6]
310
8.1 [7.2–9.1]
182
7.2 [6.2–8.4]
157
6.2 [5.2–7.2]
246
6.4 [5.6–7.3]
2,128
84.4 [82.9–85.9]
2175
85.4 [83.9–86.8]
3,267
85.5 [84.2–86.6]
20–2936
13.8 [9.8–18.7]
22
9.2 [5.8–13.7]
43
12.6 [9.2–16.6]
11
4.2 [2.1–7.5]
13
5.4 [2.9–9.2]
16
4.7 [2.6–7.5]
213
81.9 [76.6–86.5]
204
85.4 [80.2–89.6]
283
82.7 [78.3–86.7]
30–3938
11.7 [8.3–15.7]
34
10.6 [7.4–14.5]
55
11.9 [9.1–15.3]
47
14.4 [10.7–18.8]
37
11.5 [8.2–15.6]
53
11.5 [8.7–14.8]
241
73.9 [68.8–78.7]
250
77.9 [72.9–82.4]
353
76.6 [72.4–80.4]
40–4960
13.2 [10.2–16.8]
58
12.6 [9.6–16]
73
10.8 [8.5–13.4]
43
9.5 [6.9–12.6]
40
8.7 [6.2–11.7]
57
8.4 [6.4–10.8]
350
77.3 [73.1–81.1]
364
78.8 [74.7–82.5]
549
80.9 [77.6–83.8]
50+77
5.2 [4.1–6.5]
100
6.6 [5.3–8.0]
139
5.9 [5.0–7.0]
81
5.5 [4.3–6.8]
67
4.4 [3.4–5.6]
120
5.1 [4.2–6.1]
1,324
89.3 [87.6–90.9]
1,357
89.0 [87.3–90.6]
2,082
88.9 [87.5–90.2]

Abbreviations: CI, confidence interval; JGAP, representative sample of the Japanese general adult population.

Prevalence of individual TNP use

Cigarette smoking prevalence decreased from 17.6% in Y1 to 16.0% in Y3, while the use prevalence of other TNPs, including HTPs and e-cigarettes, increased (Table 3). The use prevalence of all HTP brands (i.e., IQOS, Ploom/Ploom Tech, and glo) increased across Y1-Y3, and, of all HTP brands surveyed, IQOS had the highest use prevalence (Y1-Y3: 1.8%, 3.2%, 3.3%). The use prevalence of e-cigarettes increased from 0.7% to 1.6% to 2.0% during Y1-Y3.

Table 3. Prevalence of individual TNP use in the JGAP samples overall and by sex and age group.

Number (n) and percentage (% [95% CI])
Study
year*
Cigarettes**IQOSE-cigarettes
Overall
1852
17.6 [16.5–18.7]
86
1.8 [1.4–2.2]
35
0.7 [0.5–1.1]
2825
17.3 [16.2–18.5]
152
3.2 [2.7–3.8]
76
1.6 [1.2–2.0]
31150
16.0 [15.1–17.0]
240
3.3 [2.9–3.8]
146
2.0 [1.7–2.4]
Sex
1654
28.2 [26.3–30.1]
70
3.0 [2.3–3.8]
25
1.1 [0.6–1.6]
    Men2630
28.4 [26.5–30.4]
114
5.1 [4.2–6.2]
59
2.7 [2.0–3.5]
3882
26.3 [24.8–27.9]
181
5.4 [4.6– 6.3]
104
3.1 [2.5–3.8]
1198
7.9 [6.89.0]
16
0.6 [0.3–1.1]
10
0.4 [0.1–0.8]
    Women2195
7.7 [6.6–8.8]
38
1.5 [1.0–2.1]
17
1.1 [0.3–1.1]
3268
7.0 [6.2–7.9]
59
1.5 [1.1–2.0]
42
1.1 [0.7–1.5]
Age group (years)
198
18.6 [15.322.2]
20
3.8 [2.3–5.8]
9
1.7 [0.7–3.3]
    2029270
15.1 [11.9–18.8]
23
5.0 [3.1–7.4]
14
3.0 [1.6–5.1]
3108
15.4 [12.8–18.4]
37
5.3 [3.7–7.3]
22
3.1 [1.9–4.8]
1172
23.9 [20.827.2]
23
3.2 [2.0–4.8]
6
0.8 [0.3–1.9]
    30–392145
21.8 [18.625.2]
58
8.7 [6.6–11.2]
16
2.4 [1.3–3.9]
3196
20.2 [17.7–23.0]
87
9.0 [7.2–11.0]
38
3.9 [2.7–5.4]
1214
24.6 [21.727.7]
25
2.9 [1.8–4.3]
9
1.0 [0.4–2.0]
    40492196
22.2 [19.5–25.2]
36
4.1 [2.8–5.7]
23
2.6 [1.6–3.9]
3270
20.4 [18.2–22.7]
62
4.7 [3.6–6.0]
37
2.8 [1.9–3.9]
1368
13.5 [12.2–14.9]
18
0.7 [0.3–1.1]
11
0.4 [0.2–0.8]
    50+2414
15.0 [13.7–16.5]
35
1.3 [0.8–1.8]
23
0.8 [0.5–1.3]
3576
13.8 [12.7–14.9]
54
1.3 [0.9–1.7]
49
1.2 [0.8–1.6]

Abbreviations: CI, confidence interval; JGAP, representative sample of the Japanese general adult population; TNP, tobacco or nicotine-containing product.

*Year 1 (2016/2017), Year 2 (2017/2018), and Year 3 (2018/2019)

**Cigarettes include hand-rolled cigarettes

In each of Y1-Y3, cigarette smoking was more prevalent among men (Y1-Y3: 28.2%, 28.4%, and 26.3%) than women (Y1-Y3: 7.9%, 7.7%, and 7.0%) and was highest among 40–49-year-olds (Y1-Y3: 24.6%, 22.2%, and 20.4%). The IQOS use prevalence in each of Y1-Y3 was higher among men (Y1-Y3: 3.0%, 5.1%, and 5.4%) than women (Y1-Y3: 0.6%, 1.5%, and 1.5%) and was highest among 20–29-year-olds (3.8%) in Y1, but shifted to be highest among 30–39-year-olds in Y2 (8.7%) and Y3 (9.0%). In both Y1 (1.7%) and Y2 (3.0%), e-cigarette use prevalence was highest among 20–29-year-olds, but in Y3 shifted to be highest among 30–39-year-olds (3.9%; Table 3).

Patterns of TNP use

Across Y1-Y3 (Table 4), exclusive use of only one type of TNP decreased (Y1-Y3: 82.3%, 75.0%, and 70.4%), while dual use of two types of TNPs increased (Y1-Y3: 14.3%, 17.2%, and 16.7%) and poly-TNP use increased markedly (Y1-Y3: 2.1%, 6.1%, and 10.0%).

Table 4. TNP use patterns in the JGAP samples.

Number (n) and percentage (% [95% CI])
Year 1
(2016/2017)
(n=887)
Year 2
(2017/2018)
(n=900)
Year 3
(2018/2019)
(n=1,304)
Exclusive use730
82.3 [79.6–84.8]
675
75.0 [72.0–77.8]
918
70.4 [67.8–72.9]
    Cigarettes*705
79.5 [76.6–82.1]
613
68.1 [64.9–71.2]
822
63.0 [60.3–65.7]
    IQOS22
2.5 [1.5–3.8]
43
4.8 [3.4–6.4]
69
5.3 [4.1–6.7]
    E-cigarettes3
0.3 [0.0–1.0]
10
1.1 [0.5–2.1]
6
0.5 [0.1–1.0]
    One other TNP-9
1.0 [0.4–1.9]
21
1.6 [ 0.9–2.5]
Dual use127
14.3 [12.0–16.8]
155
17.2 [14.8–19.9]
218
16.7 [14.7–18.9]
    Cigarettes + other product64
7.2 [5.6–9.2]
72
8.0 [6.3–10.0]
110
8.4 [6.9–10.1]
    Cigarettes + IQOS40
4.5 [3.2–6.1]
62
6.9 [5.3–8.8]
62
4.8 [3.6–6.1]
    Cigarettes + e-cigarettes13
1.5 [0.7–2.5]
15
1.7 [0.9–2.8]
11
0.8 [0.4–1.6]
    IQOS + e-cigarettes5.0
0.6 [0.1–1.4]
4
0.4 [0.1–1.2]
15
1.2 [0.6–1.9]
    IQOS + other product4
0.5 [0.1–1.2]
2
0.2 [0.0–0.9]
11
0.8 [0.4–1.6]
    E–cigarettes + other product1
0.1 [0.0–0.7]
-8
0.6 [0.2–1.3]
    Two other products 1
0.1 [0.0–0.5]
Poly use19
2.1 [1.2–3.4]
55
6.1 [4.6–7.9]
131
10.0 [8.4–11.9]
    Cigarettes + IQOS + e-cigarettes10
1.1 [0.5–2.1]
16
1.8 [1.0–2.9]
36
2.8 [1.9–3.9]
    Cigarettes + IQOS + other product(s)4
0.5 [0.1–1.2]
7
0.8 [0.3–1.6]
18
1.4 [0.8–2.2]
    Cigarettes + e-cigarettes + other product(s)3
0.3 [0.0–1.0]
18
2.0 [1.1–3.2]
45
3.5 [2.5– 4.6]
    Cigarettes + other products2
0.2 [0.0–0.9]
1
0.1 [0.0–0.7]
8
0.6 [0.2–1.3]
    Cigarettes + IQOS + e-cigarettes + other product(s)9
1.0 [0.4–1.9]
18
1.4 [0.8–2.2]
    IQOS + e-cigarettes + other product(s)4
0.4 [0.1–1.2]
5
0.4 [0.1–0.9]
    IQOS + other products1
0.1 [0.0–0.5]
    E-cigarettes + other products
    Three or more other products
Undefined11
1.2 [0.6–2.3]
15
1.7 [0.9–2.8]
37
2.8 [2.0–3.9]

Abbreviations: CI, confidence interval; JGAP, representative sample of the Japanese general adult population.

*Cigarettes include hand-rolled cigarettes

Across Y1-Y3 (Table 4), the greatest proportion, although declining, of participants who reported TNP use were exclusive cigarette smokers (Y1-Y3: 79.5%, 68.1%, and 63.0%), while conversely, the proportion of exclusive IQOSTM users increased (Y1-Y3: 2.5%, 4.8%, and 5.3%), and that of exclusive e-cigarette users remained low (Y1-Y3: 0.3%, 1.1%, and 0.5%).

Frequency and Intensity of TNP use

Among the participants in the JGAP samples in Y1-Y3 who were currently using cigarettes (Y1-Y3: n=852; n=825; and n=1,150), the average number of cigarettes smoked per day (over the last 30 days) appeared to be stable (Y1-Y3: 16.0, 15.7, and 15.5) (Table 5).

Table 5. Frequency and intensity of cigarette consumption among current cigarette smokers in the JGAP samples and of HEETS/HeatSticks™ consumption among current IQOS users in the JAIQOS samples across the three study years.

Mean [95% CI]
Year 1*Year 2Year 3
Current cigarette smokers — JGAP(n=852)(n=825)(n=1,150)
   Cigarettes smoked per day
      Number of days of cigarette smoking in the last 30 days29.4 [29.1–29.7]29.2 [28.9–29.5]29.3 [29.0–29.5]
      Average number of cigarettes smoked per day (based on
smoking days only)
16.2 [15.5–16.8]15.9 [15.3–16.6]15.8 [15.3–16.3]
      Average number of cigarettes smoked per day in terms
of the last 30-day period
16.0 [15.3–16.6]15.7 [15.1–16.4]15.5 [14.9–16.0]
Current IQOS™ users — JAIQOS(n=2,000)(n=2,044)(n=2,013)
   HEETS/HeatSticks used per day
      Number of days of IQOS™ use in the last 30 days29.1 [28.9–29.3]28.9 [28.7–29.1]28.8 [28.5–29.0]
      Average number of HEETS/HeatSticks used per day
(based on usage days only)
16.2 [15.8–16.6]16.5 [16.1–16.9]15.9 [15.5–16.3]
      Average number of HEETS/HeatSticks used per day in
terms of the last 30-day period
15.9 [15.5–16.3]16.1 [15.7–16.5]15.5 [15.1–15.9]

Abbreviations: CI, confidence interval; JAIQOS, sample of adult Japanese IQOS™ users from PMI’s IQOS owner database in Japan; JGAP, representative sample of the Japanese general adult population; PMI, Philip Morris International

* Year 1 (2016/2017), Year 2 (2017/2018), Year 3 (2018/2019)

TNP initiation/relapse/reinitiation

Among the participants who were never TNP users 12 months prior to the survey (Y1-Y3: n=3,066; n=3,109; and n=4,685), TNP use initiation with cigarettes in the preceding 12 months was considerably higher (Y1-Y3: 0.2%, 0.3%, and 0.2%) than initiation with IQOS (Y1-Y3: 0.03%, 0.1%, and 0.1%) (Table 6).

Table 6. TNP initiation in JPAG samples among never TNP users.

Never TNP Users
Number (n) and percentage (% [95% CI])
Year 1*
(n=3,066)
Year 2
(n=3,109)
Year 3
(n=4,685)
Initiation with
    Cigarettes**7
0.2 [0.0–0.5]
9
0.3 [0.1–0.6]
10
0.2 [0.1–0.4]
    IQOS™ with HEETS/HeatSticks1
0.03 [0.0–0.2]
4
0.1 [0.0–0.4]
5
0.1 [0.0–0.3]

Abbreviations: CI, confidence interval, JAIQOS, sample of adult Japanese IQOS™ users from PMI’s IQOS owner database in Japan; JGAP, representative sample of the Japanese general adult population; NA, not applicable; PMI, Philip Morris International; TNP, tobacco or nicotine-containing product.

*Year 1 (2016/2017), Year 2 (2017/2018), and Year 3 (2018/2019)

** Cigarettes include hand-rolled cigarettes

Note: Initiation with e-cigarettes was not measured as part of the study.

Among current TNP users in Y1-Y3 (Y1-Y3: n=894; n=900; and n=1,304), in each year only one participant reinitiated TNP use with IQOSTM (Y1-Y3: 0.1%, 0.1%, and 0.07%). No relapse to IQOS use was reported in any of the three study years (Table 7).

Table 7. Relapse and reinitiation of TNP use with IQOS™ among current TNP users in the JGAP samples.

Current TNP users Number (n) and
percentage (% [95% CI])
Year 1*
(n=894)
Year 2
(n=900)
Year 3
(n=1,304)
Relapse to IQOS0
0.0 [0.0–0.5]
0
0.0 [0.0–0.5]
0
0.0 [0.0–0.3]
Reinitiation with IQOS 1
0.1 [0.0–0.7]
1
0.1 [0.0–0.7]
1
0.07 [0.0–0.5]

Abbreviations: CI, confidence interval; JGAP, representative sample of the Japanese general adult population; TNP, tobacco or nicotine-containing product.

*Year 1 (2016/2017), Year 2 (2017/2018), and Year 3 (2018/2019)

TNP use in the JAIQOS samples

Patterns of TNP Use

Across Y1-Y3, a decreasing majority of participants in the samples used IQOSTM exclusively (Y1-Y3: 63.4%, 52.3%, and 49.4%), while the proportion who used IQOS together with other smoke-free TNPs increased (Y1-Y3: 7.6%, 17.7%, and 27.0%) and the proportion who used IQOS together with combustible TNPs decreased (Y1-Y3: 28.4%, 25.4%, and 23.6%). Consequently, by Y3, a greater proportion of participants used IQOS together with other smoke-free TNPs than IQOS together with combustible TNPs (Table 8).

Table 8. Distribution of TNP use patterns in the JAIQOS sample

Number (n) and percentage (% [95% CI])
Year 1*
(n=1,946)
Year 2
(n=1,972)
Year 3
(n=1,977)
IQOS™ only1,234
63.4 [61.2–65.6]
1,032
52.3 [50.1–54.6]
976
49.4 [47.1–51.6]
IQOS + combustible TNP552
28.4 [26.3–30.5]
501
25.4 [23.4–27.4]
467
23.6 [21.7–25.6]
IQOS + smoke-free TNP148
7.6 [6.4–8.9]
350
17.7 [16.0–19.6]
534
27.0 [25.0–29.1]
Undefined12
0.6 [0.3-1.1]
89
4.5 [3.6-5.6]
0

Abbreviations: CI, confidence interval; JAIQOS, sample of adult Japanese IQOS users from PMI’s IQOS™ owner database in Japan; JGAP, representative sample of the Japanese general adult population; PMI, Philip Morris International; TNP, tobacco or nicotine-containing product.

*Year 1 (2016/2017), Year 2 (2017/2018), and Year 3 (2018/2019)

Frequency and intensity of TNP use

In each of Y1-Y3 (Table 5), the average number of days of IQOSTM use in the last 30 days (Y1-Y3: 29.1, 28.9, and 28.8) and the average number of HEETSTM/HeatSticksTM used on the days of IQOS use in the last 30 days (Y1-Y3: 16.2, 16.5, and 15.9) were relatively stable. Thus, the average daily HEETS/HeatSticks consumption (over the last 30 days) across Y1-Y3 was similarly stable (Y1-Y3: 15.9, 16.1, and 15.5).

History of TNP use

In each of Y1-Y3, the majority of the JAIQOS sample participants had a smoking history before starting IQOSTM use (Y1-Y3: 98.0%, 98.7%, and 99.3%), while only a few were never smokers (Y1-Y3: 2.0%, 1.3%, and 0.7%) before starting IQOS use.

Discussion

The present study is the first to report data on the prevalence and patterns of TNP use in samples of the Japanese general adult population (JGAP) and samples of Japanese adult IQOS users (JAIQOS) over the same three consecutive years (2016/2017, 2017/2018, and 2018/2019). The findings of this study are consistent with the trends observed by other surveys that have examined the prevalence and patterns of TNP use since the introduction of the HTP IQOSTM in Japan in 20142731.

In the JGAP samples, the prevalence of overall TNP use was stable (~18%) across the study years. However, there was a trend towards a declining prevalence of cigarette smoking concurrent with an increase in smoke-free TNP and total HTP use, especially in the case of IQOSTM use (from 1.8% in 2016/2017 to 3.3% in 2018/2019).

It can, therefore, be concluded that the introduction of smoke-free TNPs does not lead to an unintended increase in overall TNP use in the general population, but rather drives a shift in TNP use patterns from cigarettes to smoke-free TNPs. When considered alongside the low TNP initiation rates with IQOSTM, the present findings further imply that introduction of smoke-free TNPs does not lead to an unintended increase in TNP use among non-users. This hypothesis is partially supported by the findings of other studies32,33 and is consistent with the findings of Cummings et al.4, who reported an accelerated reduction in cigarette sales in Japan concurrent with the introduction and increase in HTP sales. In agreement with Cummings et al.4 and others30,31, the total HTP use prevalence in year 3 of the present study was over 5%. A previous study had reported a total HTP use prevalence of 11%34. The prevalence of cigarette smoking observed in each year of the present study was in agreement with the prevalence data from the Japan National Health and Nutrition Survey for 2017 (18.8%)27, 2018 (18.9%)28, and 2019 (17.7%)29. Additionally, the present cigarette and overall TNP use data were well in line with those from other contemporaneous surveys30,31,35,36. Tabuchi et al.32 reported an IQOS use prevalence of 3.6% in 2017, which is higher than that observed in the present study (1.8%) for the same year. For 2018, Sutanto et al.37 reported an any-brand HTP use prevalence (i.e., IQOS, glo, and Ploom/Ploom Tech) of 2.7%, which is less than that observed in our study (3.2%) for IQOS use alone. These discrepancies are likely due to methodological differences (i.e., cross-sectional vs. longitudinal design or in-person vs. online interview) as described previously23.

In the JAIQOS samples, the age and sex distribution observed in each study year as well as the current HTP use patterns are in line with the Japan National Health and Nutrition Survey results for the same years2729. Similarly, in agreement with the Japanese national survey2729, the results presented here indicate that the majority of HTP users are using HTP exclusively. The average number of HEETSTM/HeatSticksTM used per day (Y1-Y3: 15.9, 16.1, and 15.5, respectively) in the JAIQOS samples was relatively stable across the study years and comparable with the 14.3 HEETS/HeatSticks used per day reported in Japan by Jones et al.31 in 2019. Moreover, the HEETS/HeatSticks consumption per day in the JAIQOS samples was very close to the average number of cigarettes consumed per day (Y1-Y3: 16.0, 15.7, and 15.5, respectively) among cigarette smokers in the JGAP samples, suggesting that IQOS users are not increasing their daily consumption upon switching from cigarettes to IQOS.

TNP initiation, relapse, and reinitiation rates observed with IQOSTM in the present study were relatively low in all three years, indicating that IQOS uptake was limited to existing smokers who had switched to IQOS. Similarly, Sutanto et al.37 concluded that “virtually all HTP users were current cigarette smokers (67.8%) or former smokers (25.0%); and that only 1.0% of HTP users were never smokers.” Jones et al.31 observed that HTP uptake in 2019 occurred “almost exclusively among current tobacco users in Japan, with negligible uptake among never tobacco users.” In both samples in the present study, nearly all current IQOS users had started TNP use with cigarette smoking. These findings suggest that IQOS uptake is occurring among current adult smokers, which is in alignment with both the principles of harm reduction and the United States Food and Drug Administration’s (FDA) conclusion that IQOS has “potential benefit to population health.”20

Major strengths of this study, among those previously described23, include the annual repeated data collection using the same sampling framework and methods, face-to-face interviews, and nationally representative samples. The limitations of the current study include all biases typically associated with self-reported measures, such as recall, social desirability, or response bias as well as sampling and selection bias. To overcome these limitations, particularly in the JAIQOS sample, the response rates were monitored and compared against preestablished quotas on the basis of age and sex.

Conclusions

While cigarette smoking remains the most prevalent way of consuming TNPs in Japan, a significant and growing number of adult Japanese smokers have switched to smoke-free alternatives such as IQOSTM, with the majority using these products exclusively. Additionally, there has been low initiation with IQOS among TNP never and former users. Taken together, the findings of the present study on the prevalence and patterns of IQOS use indicate that IQOS use behavior trends are in line with the principles of tobacco harm reduction and that HTPs are effective tools for complementing current tobacco control efforts14.

Data availability

Underlying data

INTERVALS: YEAR 1–3 DATA (SAS DATASETS, CC-BY 4.0), https://doi.org/10.26126/intervals.r35iml.138

This project contains the following underlying data:

  • SAS datafiles in the Clinical Data Interchange Standards Consortium (CDISC) Analysis Data Model (ADaM) structure (www.cdisc.org/standards) for each of the study years 1–3.

    • The ADSL (adsl_y1_jp.sas7bdat, adsl_y2_jp.sas7bdat, and adsl_y3_jp.sas7bdat,) datasets are the Subject Level Analysis Datasets and contain the main information on participants identifier, demographics, and tobacco and/or nicotine product use groups and patterns to facilitate analysis and interpretation of analysis.

    • The ADQS (adqs_y1_jp.sas7bdat, adqs_y2_jp.sas7bdat, and adqs_y3_jp.sas7bdat) datasets are the Questionnaire Analysis Datasets and contain specific information on the study survey, i.e., all questions and items answered by participants in the survey.

    • The ADEX (adex_y1_jp.sas7bdat, adex_y2_jp.sas7bdat, and adex_y3_jp.sas7bdat) datasets are the Exposure Analysis Datasets and contain specific information on the TNP use exposure, i.e., all questions and items answered by participants in the survey related to their product use.

    • The ADAM Metadata Files (ADaM_PMX01JP_AnY1_Metadata, ADaM_PMX01JP_AnY2_Metadata, and ADaM_PMX01JP_AnY3_Metadata) contain the datasets and variable labels and definitions, code lists to decode the variables names, terms and values, and the methods and computational algorithms to derive the analytical datasets.

Extended data

INTERVALS: Tobacco Use Prevalence Questionnaire. https://doi.org/10.26126/intervals.rxhx4a.138

This project contains the following extended data:

  • Tobacco Use Prevalence questionnaire (Tobacco Use Prevalence Questionnaire_engl_jap.pdf) is the questionnaire administered in the general population and IQOS user surveys (English and Japanese version).

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Reporting guideline

This study followed the STROBE reporting guideline.

INTERVALS: STROBE checklist and flow chart for “Trends in Prevalence and Patterns of Use of a Heated Tobacco Product (IQOS™) in Japan: A 3-Year Repeated Cross-Sectional Study”, are available: https://doi.org/10.26126/intervals.dluspw

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 30 Jun 2022
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Fischer K, Bajec M, Mainy N et al. Trends in prevalence and patterns of use of a heated tobacco product (IQOSTM) in Japan: A three-year repeated cross-sectional study [version 1; peer review: 2 approved with reservations]. F1000Research 2022, 11:720 (https://doi.org/10.12688/f1000research.122491.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 30 Jun 2022
Views
29
Cite
Reviewer Report 21 Sep 2022
David T. Levy, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA 
Approved with Reservations
VIEWS 29
This study provides interesting results on trends in IQOS use as related to smoking and vaping. The methodology and results are well presented. With regards to data underlying the results, I don’t recall that the authors provided for data transferred to ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Levy DT. Reviewer Report For: Trends in prevalence and patterns of use of a heated tobacco product (IQOSTM) in Japan: A three-year repeated cross-sectional study [version 1; peer review: 2 approved with reservations]. F1000Research 2022, 11:720 (https://doi.org/10.5256/f1000research.134482.r144380)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 30 Nov 2022
    Karina Fischer, PMI R&D, Philip Morris Products S.A., Neuchâtel, 2000, Switzerland
    30 Nov 2022
    Author Response
    Author Responses to Comments of Reviewers
    We thank Reviewer 1 and Reviewers 2 for their critical and comprehensive review as well as their constructive suggestions to improve the manuscript. We ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 30 Nov 2022
    Karina Fischer, PMI R&D, Philip Morris Products S.A., Neuchâtel, 2000, Switzerland
    30 Nov 2022
    Author Response
    Author Responses to Comments of Reviewers
    We thank Reviewer 1 and Reviewers 2 for their critical and comprehensive review as well as their constructive suggestions to improve the manuscript. We ... Continue reading
Views
42
Cite
Reviewer Report 28 Jul 2022
Mohamadi Sarkar, Center for Research and Technology, Altria Client Services LLC, Richmond, VA, USA 
Brendan Noggle, Center for Research and Technology, Altria Client Services LLC, Richmond, VA, USA 
Approved with Reservations
VIEWS 42
17/10/22: The reviewers' COI statement, "The reviewers are employees of Altria Client Services LLC.", was updated to include more detail on the potential link between the funders of this research and the reviewers, which was not fully declared at the ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Sarkar M and Noggle B. Reviewer Report For: Trends in prevalence and patterns of use of a heated tobacco product (IQOSTM) in Japan: A three-year repeated cross-sectional study [version 1; peer review: 2 approved with reservations]. F1000Research 2022, 11:720 (https://doi.org/10.5256/f1000research.134482.r142791)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 30 Nov 2022
    Karina Fischer, PMI R&D, Philip Morris Products S.A., Neuchâtel, 2000, Switzerland
    30 Nov 2022
    Author Response
    Author Responses to Comments of Reviewers
    We thank Reviewer 1 and Reviewers 2 for their critical and comprehensive review as well as their constructive suggestions to improve the manuscript. We ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 30 Nov 2022
    Karina Fischer, PMI R&D, Philip Morris Products S.A., Neuchâtel, 2000, Switzerland
    30 Nov 2022
    Author Response
    Author Responses to Comments of Reviewers
    We thank Reviewer 1 and Reviewers 2 for their critical and comprehensive review as well as their constructive suggestions to improve the manuscript. We ... Continue reading

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 30 Jun 2022
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.